PCSK9 and Hypercholesterolemia: Indeed, according to the European Atherosclerosis Society (EAS) Familial Hypercholesterolemia Studies Collaboration (FHSC) global registry, use of PCSK9 inhibitors among patients with HeFH was associated with greater odds of having LDL-C lower than 1.8 mmol/L [12].